Current Diabetes Reports

, Volume 10, Issue 4, pp 257–260 | Cite as

Use of Medications to Lower Urine Protein Level in Patients With Diabetic Kidney Disease

Clinical Trial Report
  • 45 Downloads

Notes

Disclosure

No potential conflict of interest relevant to this article was reported.

References

  1. 1.
    ONTARGET Investigators, Yusuf S, Teo KK, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.CrossRefPubMedGoogle Scholar
  2. 2.
    Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987, 147:943–944.CrossRefPubMedGoogle Scholar
  3. 3.
    Ninomiya T, Perkovic V, de Galan BE, et al.: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813–1821.CrossRefPubMedGoogle Scholar
  4. 4.
    Gerstein HC, Mann JF, Yi Q, et al.: Events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.CrossRefPubMedGoogle Scholar
  5. 5.
    Mauer M, Zinman B, Gardiner R, et al.: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Slagman MC, Navis G, Laverman D: Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens 2010, 19:140–152.CrossRefPubMedGoogle Scholar
  7. 7.
    Chatzikyrkou C, Menne J, Haller H: How to achieve renal protection in light of ONTARGET? J Hypertens 2009, 27(Suppl 2):S15–S17.CrossRefGoogle Scholar
  8. 8.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.CrossRefPubMedGoogle Scholar
  9. 9.
    Krum H, Carson P, Farsang C, et al.: Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004, 6:937–945.CrossRefPubMedGoogle Scholar
  10. 10.
    Blacher J, Amah G, Girerd X, et al.: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997, 10:1326–1334.CrossRefPubMedGoogle Scholar
  11. 11.
    Duprez DA, De Buyzere ML, Rietzschel ER, et al.: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998, 19:1371–1376.CrossRefPubMedGoogle Scholar
  12. 12.
    Farquharson, CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594–597.PubMedGoogle Scholar
  13. 13.
    Tian WN, Braunstein LD, Pang J, et al.: Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 1998, 273:10609–10617.CrossRefPubMedGoogle Scholar
  14. 14.
    Tian WN, Braunstein LD, Apse K, et al.: Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol 1999, 276:C1121–C1131.PubMedGoogle Scholar
  15. 15.
    Zhang Z, Apse K, Pang J, Stanton RC: High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 2000, 275:40042–40047.CrossRefPubMedGoogle Scholar
  16. 16.
    Xu Y, Osborne B, Stanton RC: Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of protein kinase A which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol 2005, 289:F1040–F1047.CrossRefPubMedGoogle Scholar
  17. 17.
    Leopold JA, Dam A, Scribner AW, et al.: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189–197.CrossRefPubMedGoogle Scholar
  18. 18.
    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.CrossRefPubMedGoogle Scholar
  19. 19.
    Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991–2002.CrossRefPubMedGoogle Scholar
  20. 20.
    McCormick BB, Sydor A, Akbari A, et al.: The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52:454–463.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of NephrologyJoslin Diabetes CenterBostonUSA

Personalised recommendations